MacroGenics Inc (NASDAQ:MGNX)
| 12.13 BATS BZX Real-Time Price As of 1:20pm ET |  -0.61 / -4.79%Today’s Change | 11.70 Today|||52-Week Range 36.48 | -24.42% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $792.1M |
Company Description
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Contact Information
MacroGenics, Inc. 9704 Medical Center Drive Rockville Maryland 20850-3368 |
Employees
Shareholders
| Mutual fund holders | 47.92% |
| Other institutional | 44.38% |
| Individual stakeholders | 26.10% |
Top Executives
| Scott E. Koenig | President, Chief Executive Officer & Director |
| James Karrels | Chief Financial Officer, Secretary & Senior VP |
| Ezio Bonvini | Chief Scientific Officer & Senior VP-Research |
| Stephen L. Eck | Chief Medical Officer & SVP-Clinical Development |
| Lynn Cilinski | Treasurer, Vice President & Controller |
